NorthWest Biotherapeutics Inc (NWBO)

[kabunushi]

Mfg capacity can be built out to that level at Sawston, but what are the barriers to getting close to that number of patients, both as a theoretical total patient population and a reasonable market penetration rate? What is the timeframe when it's possible to imagine that NW could be treating that many? Please pencil in your regulatory assumptions and ballpark figures for the numbers that NW might reasonably expect on the demand side over the next few years and on up to 15,000 patients. Let's put some meat on the bones of the bare maximum manufacturing capacity target.